Keyphrases
Clinical Trials
100%
Risk-benefit
91%
Patient Outcomes
85%
Risk Outcomes
85%
Patient Benefit
85%
Patient Risk
85%
Drug Development
85%
Adverse Events
24%
Medical Students
20%
FDA-approved Drugs
19%
Objective Response Rate
19%
Overall Survival
17%
Firefighters
17%
Ramucirumab
15%
Approved Indication
13%
Fire Department
13%
PubMed
11%
Embase
11%
Physical Health
11%
Mental Health
11%
Clinical Practice Guidelines
10%
Progression-free Survival
10%
Cochrane
10%
Patient-reported Outcomes
10%
Physician Assistant
10%
Assistant Training
10%
Call Volume
10%
Olaparib
10%
Athletic Training
10%
Wrist Actigraphy
10%
Emotional Intelligence
10%
Training Students
10%
Health Perspective
10%
Lenvatinib
10%
Afatinib
10%
Regorafenib
10%
Median Progression-free Survival
9%
Medical School
8%
Meta-analysis
8%
Systematic Meta-analysis
8%
Trial Characteristics
8%
MEDLINE
8%
Randomized Controlled Trial
8%
Off-label Indications
8%
Reporting Item
7%
Cancer Treatment
7%
Response Rate
7%
Monotherapy
7%
Breast Cancer
7%
Drug Manufacturer
7%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Drug Development
85%
Adverse Event
34%
Malignant Neoplasm
33%
Overall Survival
22%
Progression Free Survival
19%
Ramucirumab
15%
Olaparib
10%
Cross-Sectional Study
10%
Lenvatinib
10%
Afatinib
10%
Regorafenib
10%
Breast Cancer
8%
Randomized Controlled Trial
8%
Pharmaceutical Manufacturing
7%
Monotherapy
6%
Solid Malignant Neoplasm
6%
Cross Sectional Study
6%
Duvelisib
5%
Inflammatory Bowel Disease
5%
Trametinib
5%
Dabrafenib
5%
Injury
5%
Sudden Cardiac Death
5%
Heart Ventricle Arrhythmia
5%
Trastuzumab
5%
Enzalutamide
5%
Sorafenib
5%
Selinexor
5%
Abiraterone
5%
Lapatinib
5%
Pertuzumab
5%
Observational Study
5%